Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Clinical Trial Results The STEP trials established semaglutide as a breakthrough in obesity medicine
A decisive break above $949 on the back of post-earnings momentum could boost bullish sentiment in the near term
What sold me was how Eden didnt lump everyone into one plan
When evaluating the current offer, look past the headline numbers
They're designed to: Confirm the weight loss and metabolic benefits seen in Phase 2 Identify rare side effects that smaller trials might have missed Demonstrate consistent results across diverse populations (age, sex, ethnicity, comorbidities) Build long-term safety data (cardiovascular outcomes, liver health, kidney function) Provide the evidence package the FDA needs to approve the drug Retatrutide's Phase 2 results were strong enough (up to 24.2% weight loss) that Eli Lilly moved it into a large Phase 3 program
Recently theres been a dramatic shift in how these drugs are viewed and whos using themor considering using them
US$ 24.07
US$ 23.72
US$ 20.61
US$ 22.68
US$ 23.11
US$ 23.96
US$ 27.29
US$ 23.21
